P1235 Immunologic impact of chemoradiation in cervical cancer and how immune cell infiltration could lead towards personalized treatment. (1st November 2019)
- Record Type:
- Journal Article
- Title:
- P1235 Immunologic impact of chemoradiation in cervical cancer and how immune cell infiltration could lead towards personalized treatment. (1st November 2019)
- Main Title:
- P1235 Immunologic impact of chemoradiation in cervical cancer and how immune cell infiltration could lead towards personalized treatment
- Authors:
- Lippens, L
Van Bockstal, M
De Jaeghere, EA
Tummers, P
Makar, A
De Geyter, S
Van de Vijver, K
Hendrix, A
Vandecasteele, K
Denys, H - Abstract:
- Abstract : Introduction/Background: We investigated the potential of tumour-infiltrating immune cells in pre- and post-treatment tissue specimens and their changes during treatment as predictive or prognostic biomarkers for cervical cancer patients. Methodology: Cervical cancer patients treated with (chemo)radiotherapy and subsequent surgery were included in the current study. Pre- and post-treatment specimens were retrospectively analysed via immunohistochemistry. Immune cell markers for T cells (CD3, CD4, CD8, and FoxP3), macrophages (CD68 and CD163), and B cells (CD20), as well as interleukin-33 (IL33) and (programmed death-ligand 1 (PD-L1), were analysed. Patients were grouped in the low score or high score group based on the amount of positive cells on immunohistochemistry. Correlations to pathological complete response (pCR), cause-specific survival (CSS), and metastasis development during follow-up were evaluated. Results: In total, 38 patients were included. In analysis of pre-treatment biopsies, significantly more pCR was seen for patients with CD8=CD3, CD8≥CD4, positive IL33 tumour cell (TC) scores, IL33 immune cell (IC)<TC, and PD-L1 TC≥5%. Besides patients with high CD8 scores, also patients with CD8≥CD4, CD163≥CD68, or PD-L1 IC≥5% had better CSS. In analysis of post-treatment specimens, less pCR was observed for patients with high CD8 or CD163 scores. Patients with decreasing CD8 or CD163 scores between pre- and post-treatment samples showed more pCR, whereasAbstract : Introduction/Background: We investigated the potential of tumour-infiltrating immune cells in pre- and post-treatment tissue specimens and their changes during treatment as predictive or prognostic biomarkers for cervical cancer patients. Methodology: Cervical cancer patients treated with (chemo)radiotherapy and subsequent surgery were included in the current study. Pre- and post-treatment specimens were retrospectively analysed via immunohistochemistry. Immune cell markers for T cells (CD3, CD4, CD8, and FoxP3), macrophages (CD68 and CD163), and B cells (CD20), as well as interleukin-33 (IL33) and (programmed death-ligand 1 (PD-L1), were analysed. Patients were grouped in the low score or high score group based on the amount of positive cells on immunohistochemistry. Correlations to pathological complete response (pCR), cause-specific survival (CSS), and metastasis development during follow-up were evaluated. Results: In total, 38 patients were included. In analysis of pre-treatment biopsies, significantly more pCR was seen for patients with CD8=CD3, CD8≥CD4, positive IL33 tumour cell (TC) scores, IL33 immune cell (IC)<TC, and PD-L1 TC≥5%. Besides patients with high CD8 scores, also patients with CD8≥CD4, CD163≥CD68, or PD-L1 IC≥5% had better CSS. In analysis of post-treatment specimens, less pCR was observed for patients with high CD8 or CD163 scores. Patients with decreasing CD8 or CD163 scores between pre- and post-treatment samples showed more pCR, whereas those with increasing CD8 or decreasing IL33 IC scores showed a worse CSS. Meanwhile, patients with an increasing CD3 score or stable/increasing PD-L1 IC score showed more metastasis during follow-up (figure 1). Conclusion: The intratumoural immune cell landscape is a tool for prediction of outcome and response to (chemo)radiation. Disclosure: This research was supported by a research grant obtained from Roche. E.A.D. received funding from Fonds Wetenschappelijk Onderzoek (FWO) and K.V. received funding from Stichting tegen Kanker. … (more)
- Is Part Of:
- International journal of gynecological cancer. Volume 29(2019)Supplement 4
- Journal:
- International journal of gynecological cancer
- Issue:
- Volume 29(2019)Supplement 4
- Issue Display:
- Volume 29, Issue 4 (2019)
- Year:
- 2019
- Volume:
- 29
- Issue:
- 4
- Issue Sort Value:
- 2019-0029-0004-0000
- Page Start:
- A117
- Page End:
- A117
- Publication Date:
- 2019-11-01
- Subjects:
- Generative organs, Female -- Cancer -- Periodicals
616.99465 - Journal URLs:
- http://journals.lww.com/ijgc/pages/default.aspx ↗
http://www3.interscience.wiley.com/journal/118544021/toc ↗
https://ijgc.bmj.com/ ↗
http://journals.lww.com ↗ - DOI:
- 10.1136/ijgc-2019-ESGO.162 ↗
- Languages:
- English
- ISSNs:
- 1048-891X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4542.273500
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 19763.xml